Ideaya exits Werner and Pol theta
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
FDA red and green lights: April 2026
Full US approval of Gilead’s Tecartus was the only positive decision last month.
Gilead edges further away from Arcus
The disclosure comes as another of Arcus's TIGIT trials flops.
Gilead buys what it tried with Tubulis
A $3.15bn deal follows a December 2024 option agreement.
M&A analysis: Merck and Gilead splash the cash
The groups spend big on Terns and Arcellx.
MAT2A inhibition gets another endorsement
Gilead opting against IDE397 is still good news for Ideaya.
Datroway and Trodelvy's new breast cancer battle
But the Astra/Daiichi ADC stumbles in lung cancer.
Licensing analysis: Takeda saves the day
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
SABCS 2025 – Gilead hasn’t given up on its Ascent
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
Lorikeet fails to fly for MacroGenics
The company ditches lorigerlimab in prostate cancer.
